Merck, 341220-25MG, Exo1

General description
A cell-permeable methylanthranilate analog that reversibly inhibits vesicular traffic from ER to Golgi in mammalian cells (IC₅₀ = 20 µM in BSC1 cells) by inducing tubulation and collapsing of the Golgi membrane and redirecting the traffic back to ER. Acts as a potent and selective modifier of Golgi ARF1 GTPase activity. Unlike another membrane traffic inhibitor Brefeldin A (BFA; Cat. No. 203729), its effect seems to be limited to Golgi, as no effect can be detected on endocytic organelles, such as endosomes and TGN (trans-Golgi network). Its inhibitory mechanism and target(s) appear to be quite different from those of BFA and thus serves as a valuable alternative that complements BFA in membrane traffic studies.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
Golgi ARF1 GTPase
Product does not compete with ATP.
Reversible: yes
Target IC₅₀: 20 µM inhibiting vesicular traffic from ER to Golgi in BSC1 cells
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Feng. Y., et al. 2003. Proc. Natl. Acad. Sci. USA100, 6469.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Harmful (C)